CD47 antibodies and methods of use thereof

1. An isolated monoclonal antibody or immunologically active fragment thereof that binds to human CD47, said antibody or immunologically active fragment thereof comprising:

a variable heavy (VH) chain CDR1 amino acid sequence set forth in SEQ ID NO: 50, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, or SEQ ID NO: 66;

a VH chain CDR2 amino acid sequence set forth in SEQ ID NO: 51, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, or SEQ ID NO: 76;

a VH chain CDR3 amino acid sequence set forth in SEQ ID NO: 52 or SEQ ID NO: 77;

a variable light (VL) chain CDR1 amino acid sequence set forth in SEQ ID NO: 53, SEQ ID NO: 67, or SEQ ID NO: 68;

a VL chain CDR2 amino acid sequence set forth in SEQ ID NO: 54, SEQ ID NO: 69, SEQ ID NO: 70, or SEQ ID NO: 71; and

a VL CDR3 sequence set forth in SEQ ID NO: 55.

2. The antibody or immunologically active fragment thereof of claim 1 , wherein the antibody is chimeric or humanized.

3. The antibody or immunologically active fragment thereof of claim 1 , wherein the antibody or immunologically active fragment thereof prevents the human CD47 from interacting with signal-regulatory-protein α (SIRPα).

4. The antibody or immunologically active fragment thereof of claim 3 , wherein the antibody or immunologically active fragment thereof promotes macrophage-mediated phagocytosis of a CD47-expressing cell.

5. The antibody or immunologically active fragment thereof of claim 1 , wherein the antibody or immunologically active fragment thereof is of an IgG isotype selected from the group consisting of IgG1 isotype, IgG2 isotype, IgG3 isotype, and IgG4 isotype.

6. The antibody or immunologically active fragment thereof of claim 1 , wherein the antibody or immunologically active fragment thereof comprises a variable heavy (VH) chain region sequence selected from the group consisting of SEQ ID NOs: 5-30.

7. The antibody or immunologically active fragment thereof of claim 1 , wherein the antibody or immunologically active fragment thereof comprises a variable light (VL) chain region sequence selected from the group consisting of SEQ ID NOs: 31-47.

8. The antibody or immunologically active fragment thereof of claim 1 , wherein the antibody or immunologically active fragment thereof comprises a VH region sequence provided in any one of SEQ ID NOs: 5-30 and a VL region sequence provided in any one of SEQ ID NOs: 31-47.

9. The antibody or immunologically active fragment thereof of claim 8 , wherein the antibody or immunologically active fragment thereof comprises a VH region sequence provided in any one of SEQ ID NOs: 5, 7, 8, 11, 12, 15-17, 20-22, and 27-30 and a VL region sequence provided in any one of SEQ ID NOs: 31, 32, 35, 40, 41, 42, 43, 44, and 47.

10. The antibody or immunologically active fragment thereof of claim 8 , wherein the antibody comprises a combination of a VH chain region sequence and a VL chain region sequence, said combination selected from the combinations listed in Table 1.

11. The antibody or immunologically active fragment thereof of claim 1 , wherein the antibody or immunologically active fragment thereof comprises the VH CDR1 sequence set forth in SEQ ID NO: 50, the VH CDR2 sequence set forth in SEQ ID NO: 51, the VH CDR3 sequence set forth in SEQ ID NO: 52, the VL CDR1 sequence set forth in SEQ ID NO: 53, the VL CDR2 sequence set forth in SEQ ID NO: 54, and the VL CDR3 sequence set forth in SEQ ID NO: 55.

12. The antibody or immunologically active fragment thereof of claim 1 , wherein the antibody or immunologically active fragment thereof comprises the VH CDR1 sequence set forth in SEQ ID NO: 50, the VH CDR2 sequence set forth in SEQ ID NO: 72, the VH CDR3 sequence set forth in SEQ ID NO: 52, the VL CDR1 sequence set forth in SEQ ID NO: 53, the VL CDR2 sequence set forth in SEQ ID NO: 71, and the VL CDR3 sequence set forth in SEQ ID NO: 55.

13. The antibody or immunologically active fragment thereof of claim 1 , wherein the antibody binds to CD47 in a head to side orientation, wherein a VH chain of the antibody is positioned near the membrane of a CD47 expressing cell, and wherein a VL chain of the antibody occludes a SIRPα binding site on CD47.

14. The antibody or immunologically active fragment thereof of claim 1 , wherein the antibody binds to a discontinuous epitope on CD47.

15. The antibody or immunologically active fragment thereof of claim 14 , wherein the antibody binds to a CD47 loop comprising SEQ ID NO: 56.

16. The antibody or immunologically active fragment thereof of claim 14 , wherein the discontinuous epitope comprises amino acid residues Y37, K39, K41, K43, G44, R45, D46, D51, H90, N93, E97, T99, E104, or E106 of CD47 when numbered in accordance with SEQ ID NO: 147.

17. The antibody or immunologically active fragment thereof of claim 1 , wherein the antibody does not cause a significant level of hemagglutination of red blood cells, as measured by an in vitro hemagglutination assay.

18. The antibody or immunologically active fragment thereof of claim 1 , wherein the antibody or immunologically active fragment thereof is of an IgG isotype selected from IgG4P and IgGPE.

19. A pharmaceutical composition comprising the antibody or immunologically active fragment thereof of claim 1 and a carrier.

20. An isolated monoclonal antibody or immunologically active fragment thereof that binds to human CD47, said antibody or immunologically active fragment thereof comprising:

a VH CDR1, a VH CDR2, and a VH CDR3, respectively comprising the amino acid sequences of a CDR1, a CDR2, and a CDR3 within a VH chain region having the sequence set forth in any of SEQ ID NOs: 5-30; and

a VL CDR1, a VL CDR2, and a VLCDR3, respectively comprising the amino acid sequences of a CDR1, a CDR2, and a CDR3 within a VL chain region having the sequence set forth in any of SEQ ID NOs: 31-47.

21. A pharmaceutical composition comprising the antibody or immunologically active fragment thereof of claim 20 .